Becton, Dickinson and Company
BDX Healthcare Medical Instruments & Supplies
In the quarter to June 2026, revenue grew 5.44%, EPS fell 31.5%, free cash flow fell 31.6% and total debt fell 22.9%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for three.
Follow BDX
Becton, Dickinson and Company (BDX) Revenue
Becton, Dickinson and Company's revenue for fiscal 2025 was $21.8B, up 8.24% from $20.2B in fiscal 2024. Over the twelve months to 30 June 2026 it was $22.4B. Over the past ten years it has ranged from $10.3B (fiscal 2015) to $21.8B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 3 consecutive fiscal years. Becton, Dickinson and Company ranks 2nd of 50 Medical Instruments & Supplies companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $21.8B | 8.24% |
| FY2024 | $20.2B | 4.16% |
| FY2023 | $19.4B | 2.66% |
| FY2022 | $18.9B | (1.36%) |
| FY2021 | $19.1B | 19.02% |
| FY2020 | $16.1B | (7.03%) |
| FY2019 | $17.3B | 8.18% |
| FY2018 | $16.0B | 32.17% |
| FY2017 | $12.1B | (3.12%) |
| FY2016 | $12.5B | 21.41% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $5.0B | 5.71% |
| Mar 2026 | $4.7B | (10.24%) |
| Dec 2025 | $5.3B | (29.65%) |
| Sep 2025 | $7.5B | 57.98% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MDLN Medline Inc. compare | $29.7B |
| BDX Becton, Dickinson and Company | $22.4B |
| BAX Baxter International Inc. compare | $11.5B |
| ISRG Intuitive Surgical, Inc. compare | $11.0B |
| ALC Alcon compare | $10.9B |
| SOLV Solventum Corporation compare | $8.3B |
| RMD ResMed Inc. compare | $5.7B |
| WST West Pharmaceutical Services, Inc. compare | $3.3B |
| RGEN Repligen Corporation compare | $785.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BDX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement